We use cookies to understand how visitors search for and consume the information we provide, so that we can improve their experience. By browsing this website, you indicate your acceptance of the use of such cookiesAcceptRead more

Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Our products& pipeline
    • Diseases we target
    • GS010 for LHON
    • GS030 for Retinitis Pigmentosa
    • GS030 for Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
  • Investors& media
    • Company Overview
    • Press releases
    • Events & presentations
    • News and press coverage
    • Stock information
    • Governance
    • Documentation

Press releases

  • Home >
  • Investors & media >
  • Press releases
08 April 2021

GenSight Biologics Announces the Filing of its 2020 Universal Registration Document

08 April 2021

Annual General Meeting on April 29, 2021

26 March 2021

GenSight Biologics successfully raises €30 million in an oversubscribed private placement with European and US institutional investors

25 March 2021

GenSight Biologics launches a reserved offering of c. €25 million by means of an accelerated bookbuilding process

10 March 2021

GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021

15 February 2021

GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs

04 February 2021

GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non Human Primates

19 January 2021

GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update

18 January 2021

GenSight Biologics Announces its 2021 Financial Calendar

13 January 2021

GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 13
  • View next 9 articles
© 2021 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
Go back to the page of the page